Showing 798 results
- Media Release /- First-in-class therapy showed an 83% (52/63) overall remission rate in this patient population with limited treatment options and historically poor outcomes1,2- Novel approach to cancer treatment…
- Media Release /
Novartis collaborates with pop icon Cyndi Lauper to release new song in honor of World Psoriasis Day
- "Hope" is inspired by the psoriasis community and Lauper's own experience living with the disease- Song and music video are available to stream at SEEMEtoknow.com- An estimated 7.5 million people… - Media Release /- Nearly 70% of patients maintained platelet counts of ≥30×10[9]/L without rescue therapy for prolonged periods, reducing the overall risk of bleeding- More than one-third of patients permanently…
- Media Release /Consumer education campaign highlights the important role of vision in giving "everyday" athletes an invisible edge on and off the fieldNew survey uncovers that clear eyesight is more important than…
- Media Release /- Structural joint damage in psoriatic arthritis (PsA) patients taking Cosentyx® (secukinumab) was inhibited at 24 weeks versus placebo in all arms of the study(1)- PsA can lead to reduced mobility…
- Media Release /- Primary results of pivotal Kymriah™ Phase II JULIET study in relapsed/refractory DLBCL- Post-hoc sub-analysis of crizanlizumab (SEG101, formerly SelG1) SUSTAIN trial evaluating time to first sickle…
- Media Release /- PARADIGMS data also show fingolimod-treated patients had significantly fewer new brain lesions vs. those on intramuscular interferon beta-1a injections(1)- Currently there are no disease-modifying…
- Media Release /- Brolucizumab, the first and only anti-VEGF to maintain a majority of patients on a 12-week treatment schedule immediately following loading phase in Phase III trials, met primary endpoint of non-…
- Media Release /- Presentation of results from the Kisqali® (ribociclib) MONALEESA-7 Phase III trial exclusively studying premenopausal women with HR+/HER2- advanced breast cancer- New MONALEESA-2 analyses focused…
- Media Release /- Subgroup of patients had a 25% reduction in major adverse cardiovascular events when treated with canakinumab in a new analysis of Phase III CANTOS trial presented at the American Heart Association…
Pagination
- ‹ Previous page
- 1
- …
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- …
- 80
- › Next page